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Poster Session II S289NRM incidence significantly decreased over the three periods (30%,
24%, and 22%, p\0.001) mainly due to a reduced risk of death as-
sociated with organ failure (14%, 9%, and 7%, p 5 0.005) and
GVHD (7%, 3%, and 3%, p\ 0.001), which led to a significantly
improved OS (58%, 59%, and 64%, p 5 0.008). In older patients
who received allo-HCT from a related donor, NRM significantly
improved in 2005-2008 compared to 2001-2004 (29% vs 18%, p
\0.001) due to a reduced risk of death associated with organ failure
(11% vs 6%, p5 0.007) andGVHD (6% vs 3%, p5 0.11). However,
due to the increase in the incidence of relapse in 2005-2008, this
decreased NRM did not lead to an improvement of OS (51% vs
55%, p 5 0.21). In older patients who received allo-HCT from an
alternative donor, NRM and OS significantly improved in 2005-
2008 compared to 2001-2004 (NRM, 43% vs 31%; OS, 40% vs
51%, p\ 0.001). The reduction in NRM was mainly due to a de-
crease in death associated with infection (17% vs 11%, p 5 0.007)
and GVHD (7% vs 4%, p 5 0.152).
Conclusions: NRM and OS have recently improved, especially for
allo-HCT from unrelated BM or CB donors. These advances
seemed to be due to a reduced risk of death associated with
GVHD in both younger and older patients.374
OLDER SIBLING DONORS REMAIN AN EXCELLENT OPTION: OLDER
DONOR AGE AND LOWER CD34 INFUSED DO NOT ADVERSELY IMPACT
OUTCOMES FOR MATCHED SIBLING PERIPHERAL BLOOD STEM CELL
(PBSC) TRANSPLANTATION
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Intro: For unrelated donor allografts, higher cell doses improve out-
comes. Increasingly, older patient age is prompting consideration of
older sibling donors. On average, older donors mobilize PBSC less
well.We hypothesized that outcomes would be worse after older sib-
ling PBSC allografts as older age adversely impacts PBSC yields.
Methods:We reviewed transplant outcomes fromHLAmatched or
single antigen/allele mismatched siblings harvested between January
2001 and April 2008. Donors underwent uniform PBSC mobiliza-
tion of G-CSF at 10 mcg/kg/day and apheresis on day 5. We evalu-
ated the influence donor and recipient age as continuous variables.
We also explore the allograft dose by CD34 dose infused above
the median and the peripheral blood (PB) CD34 on day 5 pre-apher-
esis (a biologic measure of mobilization capacity of the donor). All
diseases and conditioning regimens were included. The majority of
patients underwent regimens incorporating campath.
Results: Of the 195 sibling donors who underwent mobilization,
182 pts (93%) were infused with PBSCs from one mobilization at-
tempt. The median donor age was 52 years (range 16-70) and
16.9% were 60 years or older. Median recipient age was 53.2 years.
The median CD34 infused was 5.4 x10(6)/kg (range 0.34 to 13.2).
The risk of acute II-IV GVHD did not correlate with older donor
age (HR 5 1.01, P0.49), recipient age (HR 5 1.04, 95%CI, 0.99-
1.09; P 5 0.06), CD34 infused above the median (HR 5 1.19, P 5
0.12), or higher pre-apheresis PB CD34 (HR 5 1.01, P 5 0.82).
However, only 22 recipients developed aGVHD. Donor age was
not associated with relapse free survival (RFS) (HR 5 1.06, P 5
0.45) or OS (HR 5 1.06, P 5 0.53). Older recipients, however,
had inferior OS (HR 5 1.02, P 5 0.014) but not RFS (HR 5 1.01,
P 5 0.30). OS was not associated with peak PB pre-apheresis
CD34 (P 5 0.73) or CD34 infused (P 5 0.85). In multivariate anal-
ysis of donor age, recipient age, disease status and CD34 infused,
higher CD34 infused did not impact OS. While older recipient
age demonstrated a strong association with poorer OS (P 5 .008),
older donor age showed a borderline associated with improved OS
(PS 5 .049).
Conclusion: After adjusting for recipient age and disease, lower
CD34 infused and older donor age had no detrimental impact on
GVHD, relapse, or OS. Absent data showing a benefit of younger
unrelated donors, we conclude that medically cleared older sibiling
donors should be considered the standard of care when available,
at least up to age 70 years.375
ALEMTUZUMAB VS ATG FOR T-CELL DEPLETION IN SIBLING DONOR RE-
DUCED INTENSITY HAEMATOPOIETIC STEM CELL TRANSPLANTATION
(RIC HSCT) FOR THE TREATMENT OF ACUTE MYELOID LEUKAEMIA
AND MYELODYSPLASTIC SYNDROME
Potter, V.T., Tindell, V.J., Reiff-Zall, L., Ho, A., Kenyon, M., Marsh, J.,
Pagliuca, A.,Mufti, G.J., Lim, Z. Kings College Hospital, London, United
Kingdom
We report the results of a retrospective analysis on 83 patients who
underwentHLA-matched sibling donor RICHSCT receiving either
ATG or alemtuzumab. All patients received a uniform protocol of
fludarabine and busulfan. For T-cell depletion/GVHD prophylaxis
48 patients received alemtuzumab(20mg x 5 days IV) followed by
cyclosporin A post-transplant. 35 patients received ATG(Thymo-
globulin, Genzyme)(total 6mg/kg over 3 days IV) followed by meth-
otrexate/cyclosporine A post-transplant.
Diagnoses included myelodysplastic syndrome (MDS)(n 5 34),
acute myeloid leukaemia (AML)(n 5 40) or MDS/MPD(n 5 9).
Median recipient age was 56yrs(range 22-72) in both groups. All pa-
tients received PBSC with median CD34 cell dose of 5.06 x106/kg.
There were no significant differences between groups with regard
to age, disease type, cytogenetic risk, disease stage at transplantation,
or CD34 cell dose. Median follow-up (for survivors) was 743 days
(range 31-1516) for ATG and 2193 days (range: 39-3595) for
alemtuzumab.
Median time to neutrophil (0.5x10^9/L) regeneration was 14 days
in both groups. There were 3 primary graft failures (1 ATG, 2 alem-
tuzumab).Median donor CD3 chimerism to day 100(alemtuzumab v
ATG) was 73% v 65% at D30, 74% v 69.5% at D60 and 67% v 44%
at D100(p5NS). A higher proportion of patients receiving alemtu-
zumab required subsequent DLI therapy (68.8 v 31.4% p 5 0.001).
The main reason for DLI in each group was falling donor chimerism
(61 v 57.1%p5NS). The incidence of de novo cGVHD was higher
in the ATG arm(25.6 v 8.3% p 5 0.06), however this was offset by
subsequent development of cGVHD in the alemtuzumab arm due
to greater DLI administration. Consequently overall rates of chronic
GVHDwere similar between alemtuzumab and ATG arms(41.2% v
40%). The 2-year OS in the ATG v alemtuzumab group was 67.8
+/2 8.5% vs 50.3 +/2 7.4%(p 5 0.38). DFS was 51 +/2 9.4% in
ATG patients, vs 38.3 +/27.1% in alemtuzumab patients. There
was no significant difference in TRMor relapse between the alemtu-
zumab vs ATG group 27+/27.5% v 15+/26.9%, (p 5 0.48), and
47.5+/27.8% vs 43.8 +/2 9.8%.
In summary, our experience indicates that in patients with MDS/
AML having sibling donor RIC HSCT, use of ATG results in com-
parable outcomes when compared with alemtuzumab, with signifi-
cantly lower need for DLI. While the incidence of GvHD is
similar between groups, ATG patients are more likely to develop
de novo GvHD when compared with alemtuzumab patients who
develop delayed GvHD following DLI.376
SILICA-INDUCED IMPAIRMENT OF MACROPHAGE FUNCTION REDUCES
GVHD SEVERITY AND IMPROVES SURVIVAL
Sega, E.I., Leveson-Gower, D.B., Negrin, R.S. Stanford University,
Stanford, CA
Acute graft versus host disease (GVHD) is a major complication of
bonemarrow transplantation (BMT). The pathogenesis of GVHD is
characterized by a cascade of inflammatory cytokines and effector
molecules that maintain a proinflammatorymilieu capable of contin-
uously activating immune cells leading to tissue injury. Several stud-
ies have demonstrated a role for macrophages in secreting these
proinflammatory mediators during GVHD progression. Silica
decreases the phagocytic capacity of macrophages and alters their ca-
pacity to activate T cells by switching from a Th1 to a Th2 response.
Therefore, we investigate whether altering macrophage function by
in vivo administration of silica would result in alleviation of GVHD
symptoms and improved survival. Mice were lethally irradiated and
transplanted with with 5x106 allogeneic T-cell depleted bone mar-
row cells (TCD-BM) and 7.5x105 allogeneic conventional T cells
(Tcon) to induce GVHD. A significant increase in median survival
S290 Poster Session IIwas observed in mice receiving a single dose of silica (3mg silica/
mouse IV) one day prior to GVHD induction as compared to mice
receiving Tcon only (77 days vs. 29 days, respectively, P 5
0.0164). This result correlated with a decrease in Tcon proliferation
as illustrated by whole body bioluminescence imaging (BLI) as well
as ex vivo imaging of lymph nodes, spleen and gastrointestinal tract.
This decrease in T con proliferation was confirmed with CFSE-la-
beled Tcon re-isolated on day 5 after BMT, with 50% of CD4+ T
cells proliferated in the pLN of control mice, yet only 30% prolifer-
ated in silica treated mice (30%, P 5 0.0004). The spleen showed
more proliferation of CD4+ T cells overall, however there was still
a significantly less proliferation in mice receiving silica than in con-
trol mice (79% and 95%, respectively, P5 0.0023). In addition, silica
treatment resulted in less overall inflammation as indicated by anal-
ysis of serum cytokine levels. In particular, significantly less IFNg,
TNF-a, IL-2, IL-4, IL-5,GM-CSF, IL-10, and IL-12were detected
in the serum from mice treated with silica than from control mice.
Together, these results suggest that silica-induced impairment of
macrophage function results in reducedT con proliferation, reduced
inflammation, and prolonged survival after GVHD induction.377
OPTIMIZATION OF ANTI-THYMOCYTE GLOBULIN EXPOSURE IN PAEDI-
ATRIC BONE MARROW TRANSPLANTATION IN ORDER TO DESIGN AN
INDIVIDUALIZED DOSING REGIMEN
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Background: Hematopoietic stem cell transplantation (HSCT) is
complicated by severe infectious complications during the lympho-
penic period after HSCT, which increases mortality and morbidity.
Anti-thymocyte globuline (ATG) is administered prior to allogeneic
HSCT to reduce risks of graft-rejection and graft versus host
(GvHD). Large interpatient variations in pharmacokinetics (PK) of
ATG have been reported, possibly due to differences in bodysize,
cell numbers prior to ATG, ‘‘the given graft’’, and other patient
characteristics.
Currently, all patients receive the same dose based on bodyweight.
This non-individualized dosage is likely to either increases the risk of
GvHD (by under dosing) or delays post-tranplant immune reconsti-
tution (by overdosing). This study aims to explain the relation
between the above mentioned patient and HSCT related character-
istics and the pharmacokinetics of ATG as a basis to design an
individualized dosing regimen.
Methods: 142 patients, ranging between 4.5 and 80 kg body weight,
who received HSCT between 2004 and 2009 in the two Dutch pedi-
atric hospitals were included. 72 patients received bone marrow, 48
cord blood and 22 peripheral stem cell transplants, containing 23 to
110 CD34+cells. A median dose of rabbit ATG (Imtix) of 10mg/kg
was given in consecutive 4 days. The level of active ATG capable
of binding to T lymphocytes (HUT 78) was measured by quantita-
tive flow cytometry (FACS), total ATG by ELISA. PK analysis was
performed using NONMEM.
Results: Large interindividual variability was observed in PK of
ATG. Preliminary results of the pharmacokinetic model of active
ATG showed a linear relationship between body weight and clear-
ance in children under approximately 20 kg body weight. In children
over 20 kg large variability was observed, which could not be ex-
plained by bodyweight. In 15 Patients, who produced IGG-
antibodies against ATG a more rapid clearance was observed in
comparison with patients who did not form antibodies.
Conclusions: The results of the pharmacokinetic model show that
a fixed dose of 10 mg/kg in all pediatric patients does not lead to
the same exposure of active ATG in all patients ranging 1 month
and 21 years of age. Optimization of the pharmacokinetic will be per-
formed in order to derive a paradigm for individualized dosing, lead-
ing to a more predictable exposure in all patients.378
INCIDENCE AND OUTCOME OF ADENOVIRUS INFECTION IN ADULT AL-
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Background:True adenovirus infection, but has been reported in 5-
20% of allogeneic hematopoietic stem cell transplant (allo HCT) re-
cipients, with\2% of patients developing severe adenoviral disease.
Adenovirus infection is generally associated with profound immuno-
suppression and a poor outcome. We evaluated the incidence and
significance of adenovirus detection among allo HCT recipients at
our institution between 1999 and 2009.
Methods: Viral culture was used to isolate adenovirus from various
sterile and non-sterile sources. An immunofluorescence assay was
used for confirmation. Definitive infection was the isolation of ade-
novirus from a sterile source with tissue invasion and compatible
clinical presentation. Probable infection represented isolation of
the virus from a non-sterile source without tissue data but with
compatible clinical features. Disseminated disease was defined as
the involvement of . 2 organs.
Results: Seventy-five patientswith at least onepositive adenovirus cul-
ture, representing 1.4%of all alloHCT recipients during the study pe-
riod,were identified.Transplant typeswerematched related (36; 48%),
matched unrelated (22; 29%), haploidentical (9; 12%), and umbilical
cord blood (8; 10%). At the time of adenovirus infection, acute (gra-
deII-IV) or chronic graft versus host disease (GVHD) was present in
18 (24%) and 30 patients (40%), respectively. Sixty-nine of these pa-
tients had probable adenovirus infection while 6 had definitive infec-
tion. Thirteen patients (17%) had disseminated disease. Median time
from allo HCT to adenovirus infection was 4.8 months (range 0.3 to
80).Eightpatients (10%) receivedanti-adenovirus treatmentwithcido-
fovir. The most common clinical manifestations were pneumonia (20,
27%),hemorrhagiccystitis (13,17%),upper respiratory tract infections
(12,16%),andenteritis (11,15%).Medianoverall survivalwas5months
and the 2-year survival was 33%. The presence of acute GVHD (p5
0.001), treatment with methylprednisolone (p5 0.0003) and dissemi-
nated adenovirus disease (p5 0.02) were associatedwith a significantly
shorter overall survival. In contrast, the type of allo HCT, use of cido-
fovir, ATG, or probable vs. definitive adenovirus infection did not have
a significant impact on survival.
Conclusions: Adenovirus infection is relatively uncommon after
allo HCT. Dissemination of adenovirus is associated with a signifi-
cantly poor outcome in patients with acute GVHD and systemic
use of steroids.379
KL-6 AS A MARKER FOR BRONCHIOLITIS OBLITERANS IN PEDIATRIC
AND YOUNG ADULT BONE MARROW TRANSPLANT PATIENTS
Flatt, T., Neville, K., Dalal, J. Children’s Mercy Hospital, Kansas City,
MO
Background: Bronchiolitis obliterans syndrome (BOS) is a serious
complication of allogeneic bone marrow transplant (BMT). There
is a need for a non-invasive diagnostic test in order to detect BOS
in transplant recipients. KL-6 is a high molecular weight glycopro-
tein classified asMUC1mucin that is expressed on the epithelial sur-
face of type II alveolar cells in the lungs and is present on the surface of
bronchiolar epithelial cells. KL-6 is an active chemotactic factor for
fibroblasts which could play a role in the early pathogenesis of BOS.
Objective:We hypothesize that serum KL-6 levels will be elevated
in subjects with known BOS.
StudyDesign:This is a case control study that employs convenience
sampling for KL-6 samples. It is a multi-center study.
Methods: Serum samples were obtained from 15 subjects that un-
derwent allogeneic BMT and 20 healthy controls between the ages
of 6 months and 30 years. Of the 15 subjects that underwent
BMT, 3 met the criteria for BOS. The definition of BOS was based
upon pulmonary function tests (a sustained drop in FEV1 of 20%
from pre-transplantation baseline) or biopsy. KL-6 levels were
